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Abstract
Background: Gene expression alterations have previously been associated with type 2 diabetes, however whether these
changes are primary causes or secondary effects of type 2 diabetes is not known. As healthy first degree relatives of people
with type 2 diabetes have an increased risk of developing type 2 diabetes, they provide a good model in the search for
primary causes of the disease.
Methods/Principal Findings: We determined gene expression profiles in skeletal muscle biopsies from Caucasian males
with type 2 diabetes, healthy first degree relatives, and healthy controls. Gene expression was measured using Affymetrix
Human Genome U133 Plus 2.0 Arrays covering the entire human genome. These arrays have not previously been used for
this type of study. We show for the first time that genes involved in insulin signaling are significantly upregulated in first
degree relatives and significantly downregulated in people with type 2 diabetes. On the individual gene level, 11 genes
showed altered expression levels in first degree relatives compared to controls, among others KIF1B and GDF8 (myostatin).
LDHB was found to have a decreased expression in both groups compared to controls.
Conclusions/Significance: We hypothesize that increased expression of insulin signaling molecules in first degree relatives
of people with type 2 diabetes, work in concert with increased levels of insulin as a compensatory mechanism, counter-
acting otherwise reduced insulin signaling activity, protecting these individuals from severe insulin resistance. This
compensation is lost in people with type 2 diabetes where expression of insulin signaling molecules is reduced.
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Introduction
Type 2 diabetes is a complex and multi-factorial disease
involving both genetics and pre- and postnatal environmental
etiological factors. The genetic importance in the pathogenesis of
type 2 diabetes is indicated by several lines of evidence from
studies of both twins and first degree relatives of people with type 2
diabetes [1]. Additionally, type 2 diabetes segregates in families,
and there are substantial differences in the prevalence between
ethnic groups and races [1]. Finally, insulin resistance is
maintained in skeletal muscle cell cultures started from biopsies
taken from people with type 2 diabetes and insulin resistant
individuals signifying that it is not only the surrounding milieu that
causes the molecular defects [2–4].
The underlying genetics of type 2 diabetes is very complex and
it is clear that several genes play a role making this a polygenic
disease. Furthermore, there are several different combinations of
the so-called ‘diabetogenes’ that can lead to type 2 diabetes under
the influence of certain environmental conditions [5–7]. Several
new type 2 diabetes gene regions have recently been identified
[8,9,10]. Whether these SNPs in or close to specific genes are part
of the underlying pathogenesis or simply markers of the disease is
still not known, although some of these variants have been linked
to impaired b-cell function and insulin secretion [11].
Skeletal muscle accounts for approximately 75% of the glucose
uptake after a meal, and accordingly has a major impact on overall
glucose homeostasis [12]. It has previously been shown that skeletal
muscle from Mexican Americans and Europeans with type 2 diabetes
has an altered gene expression profile compared to healthy control
individuals [13–15]. These changes can either be a secondary effect of
a changed metabolic milieu, a direct consequence of reduced insulin
signaling, or be part of the primary cause of the disease.
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group very interesting since they have a greatly increased risk of
developing type 2 diabetes compared to the background
population [16]. In relatives that have not developed insulin
resistance, changes in gene expression are not secondary to an
altered metabolic milieu since these individuals are not subjected
to any metabolic dys-regulation or decreased level of insulin action
[17].
Given the fact that type 2 diabetes is a polygenic disorder, the
microarray technology simultaneously measuring the expression of
thousands of genes is well suited for studies of this disease. We
determined the expression profiles in skeletal muscle from people
with type 2 diabetes, first degree relatives, and healthy control
individuals by microarray experiments. All subjects were Cauca-
sian males and biopsies were taken after a controlled metabolic
period of a two hour hyperinsulinemic euglycemic clamp. Our
results show for the first time that insulin signaling is significantly
downregulated in people with type 2 diabetes, whereas it is
significantly upregulated in first degree relatives. Furthermore, we
identify several new genes in skeletal muscle from first degree
relatives that have an altered gene expression compared to healthy
controls.
Methods
Clinical characterization of subjects and biopsy
procedure
Male subjects comprised three experimental groups; healthy
controls, people with type 2 diabetes, and first degree relatives
(Table 1). The first degree relatives were defined as people with at
least 50% of their genes in common with a person with type 2
diabetes, and were not related to the type 2 diabetic patients
participating in this study. In vivo insulin action was measured as
M-values (mg glucose/kg FFM/min) as determined during a
2 hour 40 mU/m
2/min hyperinsulinemic euglycemic clamp. The
insulin concentration was acutely raised and maintained by a
continuous infusion of insulin and the glucose concentration was
held constant at basal levels (5 mmol/L), by variable glucose
infusion. After 2 hours, biopsies were taken from the vastus
lateralis muscle of each subject using a Bergstro ¨m needle under
local anesthesia. Samples were immediately frozen in liquid
nitrogen and saved for later use.
The study protocol was in accordance with the Helsinki
Declaration II, and approved by The Danish Research Agency
(KA 01122 g), and by The Danish Data Protection Agency (J.nr.
Table 1. Clinical characteristics of subjects.
Cn=1 5 Dn=5 Rn=1 5
p-value
C vs. D
p-value
C vs. R
Mean SD Mean SD Mean SD
Age (yr) 44.6 11.5 52.2 8.8 43.5 8.0
Height (m) 1.83 0.07 1.80 0.03 1.79 0.08
Weight (kg) 90.8 13.4 110.0 17.8 91.8 11.4 0.07
W/H ratio 0.92 0.06 1.07 0.04 0.93 0.03 ,0.001
BMI (kg/m
2) 27.20 3.97 33.98 4.52 28.50 3.07 0.02
FFM (kg) 68.70 6.66 76.32 7.58 70.90 6.66 0.05
Systolic BP (mm Hg) 124 13 141 12 128 12 ,0.001
Diastolic BP (mm Hg) 73 11 85 8 78 12 0.03
FFA (mmol/L) 266 137 530 206 267 113 0.01
F-p Cholesterol (mmol/L) 5.22 1.01 4.82 0.89 5.71 0.96 ,0.001
F-p HDL (mmol/L) 1.32 0.39 1.02 0.18 1.17 0.31 0.04
F-p Triglyceride (mmol/L) 1.45 0.79 3.80 5.47 1.85 0.90
F-p LDL (mmol/L) 3.25 0.90 2.9 0.83 3.69 0.93
F-p VLDL (mmol/L) 1.03 1.42 0.63 0.22 0.82 0.42
Blood Glucose (mmol/L) Basal 4.81 0.70 7.30 1.15 4.88 0.71 0.01
Blood Glucose(mmol/L) Insulin 4.87 0.27 4.86 0.15 4.85 0.34
Plasma Insulin (pmol/L) Basal 39.3 36.2 63.4 13.4 65.9 36.8 0.04 0.06
Plasma Insulin (pmol/L) Insulin 384 97 466 26 549 248 0.01 0.03
Plasma C-peptide (pmol/L) Basal 607 310 804 239 745 296
GOX (mg glu/kg FFM/min) Insulin 3.35 0.33 1.90 0.18 3.45 0.34 ,0.001
FOX (mg glu/kg FFM/min) Insulin 0.10 0.01 1.04 0.10 0.13 0.26 ,0.001
M-value (mg glu/kg FFM/min) Insulin 11.40 3.75 5.91 1.42 9.21 3.73 0.01
NOGM (mg glu/kg FFM/min) Insulin 7.65 3.39 4.01 1.47 6.00 3.53 0.04
Average clinical data for all subjects in the three different experimental groups: healthy controls (C), people with type 2 diabetes (D), and first degree relatives (R). The
control and relative groups consisted of 15 individuals each, whereas the type 2 diabetes group consisted of 5 individuals. All subjects were Caucasian males. Glucose
and lipid oxidation was calculated using the equations suggested by Frayn [36] NOGM was calculated as the M-value – glucose oxidation rate. P-values are listed when
significant. SD: standard deviation, W/H: waist/hip, FFM: fat-free mass, BP: blood pressure, FFA: free fatty acids, HDL: high density lipoprotein, LDL: low density
lipoprotein, VLDL: very low density lipoprotein, GOX: glucose oxidation, FOX: fat oxidation, NOGM: non-oxidative glucose metabolism, F-p: fasting plasma.
doi:10.1371/journal.pone.0006575.t001
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before entering the study.
Statistical analyses were performed with SAS Statistical Analysis
Package (SAS Institute, Cary, NC, version 8.2). Two-sided
Student’s t-test was used to identify statistically significant
differences between the groups. Data are presented as mean
values6SD, and values of P#0.05 were considered to be significant.
RNA isolation, cRNA production and fragmentation, array
hybridization and scanning
After homogenization, total RNA was isolated from the skeletal
muscle biopsies using Trizol reagent from Invitrogen as specified
by the manufacturer. The RNA subsequently went through a
clean-up step using the RNeasy Mikro kit from Qiagen.
Fragmented biotinylated cRNA was made and hybridized to
Affymetrix Human Genome U133 Plus 2.0 Arrays and scanned
following guidelines from Affymetrix (www.affymetrix.com). These
arrays contain approximately 54,000 probesets representing
approximately 47,000 transcripts.
Data analysis
Cell intensity files (CEL files) were generated in the program
GCOS from Affymetrix. A quality control report was subsequently
made using Bioconductor, and the data were modeled using the
RMA (Robust Multichip Average) approach [18,19]. Compari-
sons of individual genes between groups were made in dChip
(http://biosun1.harvard.edu/complab/dchip/). The fold change
(FC) was set to .1.2, the p-value,0.05 (unpaired t-test), with a
lower 90% confidence bound of FC, and the difference between
experiment and control intensity value was set to be more than 30.
The false discovery rate (FDR) was determined using a
permutation approach and should be less than 5%.
Functional analyses were made using the program GenMAPP/
MAPPFinder [20] (http://www.genmapp.org/). Here the criteria
were set to: FC.1.2, p-value ,0.05, and the intensity value .30.
Functional analyses were also performed using the program
Ingenuity Pathway Analysis (IPA), using the FC.1.2, p-value
,0.05 criteria. The microarray data is described in accordance
with MIAME guidelines.
Quantitative RT-PCR
Quantitative RT-PCR was performed for selected genes in
order to validate the results obtained in the microarray study.
cDNA was produced from 0.5 mg of each RNA sample using the
‘High Capacity cDNA Reverse Transcription Kit’ from Applied
Biosystems. The last step of the experiments was performed using
TaqMan Low Density Arrays (customized) and the ‘TaqMan
Universal PCR Master Mix’ both from Applied Biosystems
following company guidelines. The arrays were run on the
7900HT system and data were analyzed using the SDS 2.1
software from Applied Biosystems. The Ct value for each sample
was determined at least twice on different arrays, and the average
was used to calculate relative fold changes (FC=2
2DDCt). The
PPIA (cyclophilin A) gene was used as an endogenous control.
Calculating the FC in this way, only one value including all
replicates is obtained and accordingly standard deviations are
reported for Ct values and not fold changes.
Western blot protein assessment of the Insulin Receptor
and PGC1a
Protein lysates (20 mg of total protein) from the same skeletal
muscle samples used for the microarray study were separated on
10% BIS-TRIS gels and proteins were transferred to nitrocellulose
membranes (all from Invitrogen). After blocking, the membranes
were incubated overnight with primary antibodies against IRbeta
(sc-711, Santa Cruz Biotechnology) and PGC-1alpha (sc-5816,
Santa Cruz Biotechnology) followed by a second incubation with
HRP-conjugated anti-rabbit antibody from Cell Signaling
(#7074). The signal was detected with LumiGLO reagent
(#7003, Cell Signaling) and bands were visualized using the
LAS-3000 Image-reader from Fujifilm. Band intensities were
quantified using the Multi Gauge V2.0 software (Fujifilm).
Results
We determined the gene expression profiles in skeletal muscle
biopsies from healthy individuals, people with type 2 diabetes, and
first degree relatives. For simplicity reasons these groups will be
termed ‘C’ (controls), ‘D’ (diabetics), and ‘R’ (relatives). Gene
expression values were determined using the microarray technology
from Affymetrix as described above. All subjects were Danish
Caucasian males, and all biopsies were taken after a 2 hour
hyperinsulinemic euglycemic clamp as previously described [21].
Clinical characteristics determined for the different experimental
groups are listed in Table 1. The ‘C’ and the ‘R’ group consisted of
15 individuals each, whereas the ‘D’ group consisted of 5
individuals. The ‘D’ group was slightly older and significantly more
obese as compared to the two other groups. Additionally, they were
hyperglycemic, hyperinsulinemic, had increased free fatty acid
(FFA) levels and increased blood pressure compared to healthy
controls. The first degree relatives were healthy, normoglycemic
and mildly insulin resistant as revealed by their M-values. However,
they were notably hyperinsulinemic compared to the controls.
Genes differentially expressed in skeletal muscle from
people with type 2 diabetes or first degree relatives
The expression levels of individual genes were compared
between groups using the program dChip. All genes found to be
regulated and their fold changes are listed in the online Table S1.
The genes mentioned in either the Results or the Discussion
section are listed in Table 2 and Table 3.
Employing the cutoffs described in the Methods section, 149
genes were found to be differentially expressed in the ‘D’ group
compared to controls. The majority of these genes were
downregulated (Figure 1). The generated genelist included several
noteworthy genes like the insulin receptor (INSR), insulin receptor
substrate 2 (IRS2), protein phosphatase 1 (PPP1CB), lipoprotein
lipase (LPL), hexokinase 2 (HK2), phosphorylase kinase (PHKA1),
forkhead box O3A (FOXO3A), histone deacetylase 7A (HDAC7A),
and NADH dehydrogenase (NDUFS1) (Table 2).
Using the same cutoffs, 11 genes were found to be differentially
expressed in the ‘R’ group compared to controls, however this
comparison had a FDR .5% (Figure 1). The 11 genes were the
following:Collagen1alpha1(COL1A1),collagen3alpha1(COL3A1),
growth differentiation factor 8 (GDF8), kinesin family member 1B
(KIF1B), lactate dyhydrogenase B (LDHB), PDZ and LIM domain 5
(PDLIM5), trophoblast-derived noncoding RNA (TncRNA), golgi
autoantigen, golgin subfamily A 8A (GOLGA8A), AT rich interactive
domain 5B (ARID5B), LON peptidase N-terminal domain and ring
finger 2 (LONRF2),and an EST(Table 3). Due to the higher FDR for
this comparison, changes in the majority of these genes were
validated by qRTPCR (Table 3 and online Figure S1).
Two genes, LDHB and TncRNA, were found to be differentially
expressed in both the ‘D’ and the ‘R’ group. The function of
TncRNA is currently unknown whereas LDHB is a key-enzyme in
anaerobic glycolysis. LDHB was found to be downregulated in
both the ‘R’ and the ‘D’ group compared to controls.
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Gene symbol Gene name FC microarray qRT-PCR DChip criteria
Insulin Signaling
INSR Insulin receptor 21.66 Yes Yes
IGF1R Insulin-like growth factor 1 receptor 21.37 Yes
IRS2 Insulin receptor substrate 2 21.58 Yes Yes
PIK3CA Phosphoinositide-3-kinase, catalytic, alpha 21.32 Yes
PIK3CD Phosphoinositide-3-kinase, catalytic, delta 21.44
PIK3R1 Phosphoinositide-3-kinase, regulatory subunit 1 21.49
PDPK1 3-phosphoinositide dependent protein kinase-1 21.24
SLC2A4 Solute carrier family 2 member 4 (GLUT4) 21.62 Yes
VAMP2 Vesicle-associated membrane protein 2 1.28
EHD1 EH-domain containing 1 21.29
SNX26 Sorting nexin 26 21.33
SORBS1 Sorbin and SH3 domain containing 1 21.30
CBLC Cas-Br-M ecotropic retroviral transf. sequence c 21.29
RAPGEF1 Rap guanine nucleotide exchange factor (GEF) 1 21.24
FOXO3A Forkhead box O3 21.50 Yes Yes
SRF Serum response factor 21.28
RHEB Ras homolog enriched in brain 1.33 Yes Yes
EIF4E Eukaryotic translation initiation factor 4E 1.24
RAF1 V-raf-1 murine leukemia viral oncogene homol. 1 1.29
MAPK4 Mitogen-activated protein kinase 4 21.31
MAPK8 Mitogen-activated protein kinase 8 21.23
MAPK12 Mitogen-activated protein kinase 12 21.26
MAP2K7 Mitogen-activated protein kinase kinase 7 21.53
MAP4K4 Mitogen-act. protein kinase kinase kinase kinase 4 21.44
MINK Misshapen-like kinase 1 21.32
Modulators of Insulin Action
PTPN11 Protein tyrosine phosphatase, non-R type 11 21.37
MAPK8 Mitogen-activated protein kinase 8 21.23
SOCS3 Suppressor of cytokine signaling 3 21.36
IKBKB Inhibitor of k light polypept. gene enhancer in B-cells, kinase b 21.32
PRKCA Protein kinase C, alpha 21.36
PRKCQ Protein kinase C, theta 21.3
PPP1CB Protein phosphatase 1, catalytic subunit, b isoform 21.34
PPM1A Protein phosphatase 1A, Mg-dependent, a isoform 21.22
PPM1B Protein phosphatase 1B, Mg-dependent, b isoform 21.22
PPP1R9B Protein phosphatase 1, regulatory subunit 9B 21.27
PPP2CB Protein phosphatase 2, catalytic subunit, b isoform 21.21
PPP2R5B Protein phosphatase 2, regulatory subunit B’, b 21.25
Metabolic Regulation
PFKL Phosphofructokinase, liver 21.34
LIPE Lipase, hormone-sensitive 21.34
GYS1 Glycogen synthase 1 21.29
HK2 Hexokinase 2 22.75 Yes Yes
LPL Lipoprotein lipase 21.86 Yes Yes
PHKA1 Phosphorylase kinase, alpha 1 21.51 Yes Yes
LDHB Lactate dehydrogenase B 21.90 Yes Yes
Mitochondrial Function
NDUFS1 NADH dehydrogenase 1 21.60 Yes Yes
NDUFS2 NADH dehydrogenase 2 21.37
Gene Expression Profiling
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(between 1.2 and 1.4) with some exceptions like HK2, which was
downregulated 2.75 times in the ‘D’ group compared to controls.
Quantitative RT-PCR results
Thirteen genes found to be significantly differentially expressed
in the ‘D’ group according to the chosen cutoffs in dChip, were
further investigated by qRT-PCR (online Figure S1A). All genes
were found to be regulated in the same direction with both
methods, however two of the genes (IRS2 and RHEB (Ras
homolog enriched in brain)) did not live up to the FC.1.2 criteria.
Six of the 11 genes differentially expressed in the ‘R’ group were
investigated by qRT-PCR (online Figure S1B). All genes were
found to be regulated in the same direction with either method,
however two genes (COL1A1 and COL3A1) did not meet the
FC.1.2 criteria (21.18, and 21.19 respectively).
Additionally, genes of particular interest not found on the dChip
derived genelists where investigated with qRT-PCR and the
results were compared to microarray results (online Figure S1C).
Using the qRT-PCR approach it was found that PGC1a (PPARc
coactivator 1a) was slightly downregulated in the ‘D’ group
(FC=21.20), and PGC1b (PPARc coactivator 1 b) was downreg-
ulated in the ‘R’ group (FC=21.35). However, these differences
were not statistically significant.
All Ct averages, standard deviations, and fold changes can be
seen in the online Table S2.
Functional analysis using GenMAPP/MAPPFinder and
Ingenuity Pathway Analysis
The data were compared between groups by functional analyses
using GenMAPP/MAPPFinder. Fold changes and p-values calcu-
lated in dChip were imported to the program, and the cutoffs were
the following: FC.1.2, p-value ,0.05, and the mean expression
value .30. A higher number of genes applied to these criteria, than
in the dChip analyses, where additional cutoffs were present.
The top three functions/pathways for each comparison are
shown in Table 4. It is striking that the most significantly
upregulated pathway in the first degree relatives is Insulin
Signaling, whereas it is the single most downregulated pathway
in people with type 2 diabetes. These results are highly significant
even when adjusting for multiple testing in MAPPFinder
(Adjusted p-value). The only other significant pathway after
adjusting for multiple testing is MAPK signaling, which is
downregulated in the ‘D’ group. Generally, the majority of
pathways/functions were upregulated in the relatives and
downregulated in people with type 2 diabetes. It was also a
general tendency that several pathways upregulated in the ‘R’
group become downregulated in the ‘D’ group. Besides insulin
signaling, this was for example the case for genes involved in
glycogen metabolism, muscle development, and apoptosis. Genes
involved in protein synthesis were overall upregulated in both
groups. Genes involved in mitochondrial function and electron
transport were generally downregulated, however these functions
were not found to be significantly changed compared to controls.
Another notion was that several serine/threonine phosphatases
h a dad e c r e a s e de x p r e s s i o ni ns k e l e t a lm u s c l ef r o mt h e‘ D ’g r o u p
compared to controls (PPM1A, PPM1B, PPP1R9B, PPP2CB,a n d
PPP2R5B).
Functional analyses were also made using the Ingenuity
Pathway Analysis (IPA) program, looking at general regulation
of signaling pathways not discriminating between up- and
downregulation of specific genes. The same cutoffs were used as
in the GenMAPP/MAPPFinder analyses. Overall, IPA analyses
confirmed the result obtained from the GenMAPP/MAPPFinder
analysis; namely that insulin signaling is the main signaling
pathway altered in both groups (data not shown).
The alterations in expression of genes involved in insulin
signaling found in the GenMAPP/MAPPFinder analyses can be
seen in Figure 2 and Figure 3. Some of the affected genes are
overlapping but the majority varies between the ‘D’ and the ‘R’
group. Several of the genes in this analysis did not live up to all
criteria set in the dChip analysis. The FCs observed for a subset of
the genes have been confirmed with additional qRT-PCR results
(Table 2 and Table 3)
Gene symbol Gene name FC microarray qRT-PCR DChip criteria
HK2 Hexokinase 2 22.75 Yes Yes
NNT Nicotinamide nucleotide transhydrogenase 21.55 Yes
MTRR Methyltransferase reductase 21.45 Yes
POLG Polymerase gamme 21.50 Yes
PGC1a PPARc coactivator 1a 21.05 Yes *
PGC1b PPARc coactivator 1b 1.18 Yes
Collagens
COL1A1 Collagen, type I, alpha 1 21.30 Yes
COL3A1 Collagen, type III, alpha 1 21.43 Yes
Miscellaneous
HDAC7A Histone deacetylase 7A 21.54 Yes Yes
TCF7L2 Transcription factor 7-like 2 1.11 Yes
KIF1B Kinesin family member 1B 21.23 Yes
GDF8 Growth differentiation factor 8 1.56
Table listing differentially expressed genes in people with type 2 diabetes mentioned in the results and discussion section grouped according to function/pathway
classification. The fold changes (FC) are listed for each gene. It is also indicated whether or not the microarray result has been confirmed with qRT-PCR and whether or
not the result applies to all dChip criteria used. The asterisk (*) indicate that PGC1a was found to be slightly down-regulated in the qRT-PCR experiment, which was not
the case in the microarray experiment.
doi:10.1371/journal.pone.0006575.t002
Table 2. Cont.
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In order to validate our results at the gene expression level,
protein levels of the IR and PGC1a were determined by western
blot analysis for all samples of the 3 experimental groups. Figure 4
shows the average band intensities for each group. The only
significant difference found between groups was for the IR, which is
downregulated in the ‘D’ group compared to controls. These results
correspond with our findings at the gene level. For PGC1a it is
Table 3. Genes differentially expressed in first degree relatives of people with type 2 diabetes.
Gene symbol Gene name FC microarray qRT-PCR DChip criteria
Insulin Signaling
GAB1 GRB2-associated binding protein 1 1.25 Yes
PIK3CA Phosphoinositide-3-kinase, catalytic, alpha 1.21 Yes
PIK3CB Phosphoinositide-3-kinase, catalytic, beta 1.25
PIK3R3 Phosphoinositide-3-kinase, regulatory subunit 1 21.22
PIK3C3 Phosphoinositide-3-kinase, class 3 1.21
TBC1D4 TBC1 domain family, member 4 1.24
SORBS1 Sorbin and SH3 domain containing 1 1.27
RHOQ Ras homolog gene family, member Q 1.27
SLC2A4 Solute carrier family 2 member 4 (GLUT4) 21.04 Yes
FOXO3A Forkhead box O3 1.22 Yes
RPS6KB1 Ribosomal protein S6 kinase, 70kDa, polypept. 1 1.30
SOS2 Son of sevenless homolog 2 1.25
MAPK8 Mitogen-activated protein kinase 8 1.23
MAP3K2 Mitogen-activated protein kinase kinase kinase 2 1.23
MAP3K7 Mitogen-activated protein kinase kinase kinase 7 1.21
MAP4K3 Mitogen-act protein kinase kinase kinase kinase 3 1.24
RPS6KA3 Ribosomal protein S6 kinase, 90kDa, polypeptide 3 1.21
Modulators of Insulin Action
PTPN11 Protein tyrosine phosphatase, non-R type 11 1.23
MAPK8 Mitogen-activated protein kinase 8 1.23
PRKAA2 Protein kinase, AMP-act., alpha 2 catalytic subunit 1.22
Metabolic Regulation
HK2 Hexokinase 2 21.42 Yes
LDHB Lactate dehydrogenase B 21.62 Yes Yes
LPL Lipoprotein lipase 21.31 Yes
Mitochondrial Function
PGC1a PPARc coactivator 1a 1.05 Yes
PGC1b PPARc coactivator 1b 21.18 Yes
HK2 Hekokinase 2 21.42 Yes
Collagens
COL1A1 Collagen, type I, alpha 1 21.57 Yes Yes
COL3A1 Collagen, type III, alpha 1 21.53 Yes yes
Miscellaneous
TCF7L2 Transcription factor 7-like 2 21.15 Yes
KIF1B Kinesin family member 1B 1.51 Yes Yes
GDF8 Growth differentiation factor 8 1.76 Yes Yes
PDLIM5 PDZ and LIM domain 5 1.63 Yes yes
TncRNA Trophoblast-derived noncoding RNA 1.67 Yes
GOLGA8A Golgi autoantigen, golgin subfamily a, 8A 1.57 Yes
ARID5B AT rich interactive domain 5B 1.43 Yes
LONRF2 LON peptidase NT domain & ring finger 2 1.46 Yes
Table listing differentially expressed genes in first degree relatives mentioned in the results and discussion section grouped according to function/pathway
classification. The fold changes (FC) are listed for each gene. It is also indicated whether or not the microarray result has been confirmed with qRT-PCR and whether or
not the result applies to all dChip criteria used.
doi:10.1371/journal.pone.0006575.t003
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and it is likely that this transcription factor is indeed downregulated
in some relatives and type 2 diabetic patients, but not in all.
Discussion
In this study, skeletal muscle biopsies from male subjects with
type 2 diabetes, first degree relatives, and healthy controls were
investigated at the gene expression level using the microarray
technology. The first degree relatives were slightly hyperinsulin-
emic in the fasting state and only mildly insulin resistant compared
to type 2 diabetics, making them as close to the background
population as possible. The same level of insulin resistance has
previously been found in first degree relatives [21]. The elevated
fasting plasma insulin levels in the first degree relatives support the
notion that they are in the pre-diabetic stage probably on their
way to develop overt insulin resistance. The patients with type 2
diabetes were obese, and as expected they had elevated fasting
glucose and plasma FFA levels compared to both controls and first
degree relatives (Table 1).
The biopsies were taken after a 2 hour hyperinsulinemic
euglycemic clamp thereby ensuring a constant and controlled
metabolic environment. When analyzing the data it should be kept
in mind that for genes regulated by insulin, any change in
expression could simply be a direct consequence of insulin
resistance, since the muscle tissue is subjected to high levels of
insulin during the clamp. Nonetheless, all differences seen between
groups are genuine differences since all groups were treated in the
same way. Furthermore, we were unable to completely match
subjects for advanced age and elevated BMI in this study, which
are known characteristics of patients with overt type 2 diabetes.
Accordingly, we cannot exclude the possibility that age and/or
BMI per se contributed to the differences found in patients with
type 2 diabetes. However, this does not change the overall finding
and conclusion that genes involved in insulin signaling are
upregulated in people at risk of – and prior to - type 2 diabetes
development, and subsequently are downregulated in the diabetic
state.
Overall, differences in expression were found to be modest with
FCs ranging between 1.2 and 1.4 for most genes. However, even
small changes in gene expression can have a major biological
impact, and using pathway analysis tools we show that even small
changes on an individual gene level can lead to highly significant
changes when combined for an entire pathway.
Noneofthe genesthat have beenlinkedtoincreased riskoftype2
diabetes development in GWA studies [8,9,10] were found to have
an altered expression in either group compared to the controls. This
was validated by qRTPCR analysis for the gene TCF7L2 (Table 2
Figure 1. Number of differentially expressed genes. Diagram
showing the number of genes found to be differentially expressed in
skeletal muscle biopsies from people with type 2 diabetes and first
degree relatives compared to healthy controls in a dChip analysis of the
generated microarray data. Criteria used in the analysis were set as
described in the Methods section. The number of up- and downreg-
ulated genes in each group is indicated. Only 2 genes were found to
have an altered expression in both groups, namely TncRNA and LDHB.
LDHB is a key-enzyme in anaerobic glycolysis and had a reduced
expression in both the ‘R’ and the ‘D’ group compared to controls.
doi:10.1371/journal.pone.0006575.g001
Table 4. Pathways/functions regulated on gene level.
Pathway/function Z-score Permuted p-value Adjusted p-value
First degree relatives
Insulin signaling 7.06 ,0.001 0.005 Upregulated
TGF-b signaling 6.25 ,0.001 0.068 Upregulated
RNA splicing 5.76 ,0.001 0.089 Upregulated
Focal adhesion 6.52 ,0.001 0.140 Downregulated
Inorganic anion transport 4.18 0.002 0.740 Downregulated
Inflammatory response pathway 5.59 0.003 0.326 Downregulated
People with type 2 diabetes
Apoptosis 4.31 ,0.001 0.388 Upregulated
Protein modification 2.88 0.005 0.979 Upregulated
Cell cycle G1 to S control reactome 3.47 0.006 0.676 Upregulated
Insulin signaling 6.17 ,0.001 0.002 Downregulated
MAPK signaling 5.78 ,0.001 0.002 Downregulated
G-protein signaling 4.53 ,0.001 0.078 Downregulated
The three most significantly upregulated and the three most significantly downregulated pathways/functions in skeletal muscle from people with type 2 diabetes and
first degree relatives. Results were obtained employing the program GenMAPP/MAPPFinder. Criteria were set as described in the Methods section. Pathways found to
be significantly altered after correction for multiple testing (adjusted p-value) are depicted in bold writing. Interestingly, the insulin signaling pathway was the highest
ranked upregulated pathway in the first degree relative group, whereas it was found to be the top ranked downregulated pathway in people with type 2 diabetes.
doi:10.1371/journal.pone.0006575.t004
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increased risk of type 2 diabetes. Most speculatively, it seems logical
that changes in a transcription factor like TCF7L2 will lead to
altered expression of other genes and not TCF7L2 itself. However, it
still needs to be verified that the SNPs associated to type 2 diabetes
actually play a role in diabetes development and are not simply
genetic markers for the disease.
Another general tendency was that genes and pathways found to
be upregulated in the first degree relatives of type 2 diabetics were
downregulated at the type 2 diabetic state. This phenomenon was
found to be highly significant for the insulin signaling pathway.
Expression of insulin signaling molecules is upregulated
in first degree relatives and downregulated in subjects
with type 2 diabetes
The most striking finding in this study was the highly significant
increase in expression of genes involved in insulin signaling in skeletal
muscle from first degree relatives of type 2 diabetics, and the significant
downregulation of the same pathway in type 2 diabetic skeletal muscle
s a m p l e s( T a b l e4 ,F i g u r e2 ,a n dF i g u r e3 ) .W eh y p o t h e s i z et h a tt h e
upregulation of the insulin signaling pathway at the gene expression
level observed in the relatives could be an effective compensation for
otherwise reduced insulin signaling activity. Since the first degree
relatives are hyperinsulinemic they are most likely insulin resistant in a
strictly molecular sense although not physiologically. Increased
expression of insulin signaling molecules could possibly work in
concert with increased levelsofinsulin protecting these individualsfrom
insulin resistance and metabolic dysregulation. This compensation is
later lost in type 2 diabetic muscle, and the insulin signaling pathways
are at that state downregulated. Possible explanations for the loss of this
compensatory mechanism in overt type 2 diabetes include glucose
toxicity due to elevated plasma glucose levels, lipotoxicity due to
elevated FFA levels, and/or failure of b-cell function. However, this
remains speculative until specifically addressed in future studies.
Most of the genes affected in the ‘R’ and the ‘D’ group are not
overlapping. This is for example the case for SLC2A4 (GLUT4
(Glucose transporter 4)), which is downregulated in the ‘D’ group
and unaltered in the ‘R’ group. This observation can be explained
by the fact that SLC2A4 expression is increased during a
hyperinsulinemic clamp in healthy muscle but not in type 2
diabetic muscle [22]. One of the few genes involved in insulin
signaling found in this study to be upregulated in the type 2
Figure 2. Regulation of insulin signaling in people with type 2 diabetes. The insulin signaling pathways were found to be significantly
downregulated on the gene expression level using the program GenMAPP/MAPPFinder. Analysis criteria were set as described in the Methods
section. Underneath each section of the pathway, genes found to have an increased expression are depicted in red, and genes found to have a
decreased expression are depicted in green. Figure adapted from GenMAPP.
doi:10.1371/journal.pone.0006575.g002
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residing on the GLUT4 vesicle surface and plays an important role
in the interaction between the vesicle and the plasma membrane
target [23]. An increase in the expression of proteins promoting
efficient GLUT4 trafficking and fusion to the membrane (like
VAMP2) could be a way to compensate for a decreased amount of
GLUT4 protein.
Insulin signaling defects observed in muscle from people with type 2
diabetes has previously been reported to be specific for the metabolism
regulating part of the pathway, thereby leaving the MAP kinase part of
the pathway intact [24]. However, we found that several of the MAP
kinases were downregulated at the gene expression level (Figure 2). The
decreased amount of MAP kinase expression could lead to a decreased
serine/threonine phosphorylation of for example the IRS proteins,
ultimatelyincreasinginsulinsignaling activityaspartof acompensatory
mechanism directed against insulin resistance.
We also found that several serine/threonine phosphatases had a
decreased expression in diabetic muscle compared to controls
(PPM1A, PPM1B, PPP1R9B, PPP2CB, and PPP2R5B) (Table 2).
Possibly, this reduction in phosphatase expression will translate
into an increased level of serine/threonine phosphorylation further
worsening the intensity of insulin resistance in these patients.
OXPHOS genes and PGC1a/PGC1b
Oxidative phosphorylation (OXPHOS), which has previously
been shown to be downregulated in both prediabetic relatives and
people with type 2 diabetes [13,14], was not found to be
significantly different in either group in this study. Several factors
can partly explain this divergence in results. In the study of Patti et
al., all subjects were Mexican-Americans, biopsies were taken at
basal levels and from groups of mixed sexes. Additionally,
HuGeneFL arrays from Affymetrix representing 7,129 sequences
were used in that particular study [14]. In comparison, the arrays
used in the current study had more than 50,000 probesets
representing approximately 47,000 transcripts. That fact alone is
likely to result in different findings when it comes to pathway and
functional analyses. In the study of Mootha et al., samples were
taken after a hyperinsulinemic-euglycemic clamp, all subjects were
of Caucasian origin, and the groups consisted of only males as in
the present study. However, the arrays used (HG-U133A arrays
from Affymetrix) covered only about half of the transcripts found
on the arrays used in the current study [13].
Even though the OXPHOS genes as a group were not
significantly changed at the expression level in first degree relatives
or in type 2 diabetic patients, several individual genes involved in
Figure 3. Regulation of insulin signaling in first degree relatives of people with type 2 diabetes. The insulin signaling pathways were
found to be significantly upregulated on the gene expression level using the program GenMAPP/MAPPFinder. Analysis criteria were set as described
in the Methods section. Underneath each section of the pathway, genes found to have an increased expression are depicted in red, and genes found
to have a decreased expression are depicted in green. Figure adapted from GenMAPP.
doi:10.1371/journal.pone.0006575.g003
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level of expression. NADH dehydrogenase 1 (NDUFS1), NADP
transhydrogenase (NNT), 5-methyltetrahydrofolate-homocysteine
methyltransferase reductase (MTRR), polymerase gamma (POLG),
NADH dehydrogenase 2 (NDUFS2) were among others found to
be down-regulated in the ‘D’ group (Table 2).
In this study, we could not detect any significant downregulation
of PGC1a or PGC1b in muscle biopsies from group ‘R’ or group
‘D’ (Table 2 and Table 3). A significant decreased expression of
these genes in pre-diabetic relatives and people with type 2
diabetes has previously been reported, contradicting the present
results [13,14]. However, a study of Karlsson et al. recently found
that the mRNA expression of PGC1a and PGC1b in normo-
glycemic first degree relatives was within the same range as for
healthy controls, which supports the findings of the current study
[17]. To clarify this matter, we determined the protein expression
of PGC1a in all three experimental groups, and found that
PGC1a indeed looks like it is downregulated in some first degree
relatives and diabetic patients, but not in others. Due to the high
interpersonal variation the measured downregulation is not
significant (Figure 4).
Genes with altered expression levels in first degree
relatives of type 2 diabetics
As previously mentioned, alterations in gene expression found in
healthy first degree relatives of type 2 diabetics are good
candidates when searching for underlying causes of the disease.
8 of the 11 genes found to be differentially expressed in muscle
samples from first degree relatives had an increased level of
expression compared to the controls. These genes include among
others KIF1B and GDF8. Interestingly, the expression of KIF1B
was downregulated in the ‘D’ group using both the microarray and
the qRT-PCR approach. Both of these genes could turn out to
play a crucial role in type 2 diabetes pathogenesis.
KIF1B has been shown to be highly involved in the transport of
mitochondria and KIF1B heterozygous mice have an impaired
transport of synaptic vesicle precursors and suffer from a high
degree of muscle weakness [25,26]. Type 2 diabetes has been
associated with a decreased mitochondrial level in skeletal muscle
[27]. An upregulation of mitochondrial transport by upregulation
of KIF1B could possibly be a way to compensate for a supposed
decreased mitochondrial level. Interestingly, one of the gene
regions recently found to associate with type 2 diabetes contains
KIF11 – another kinesin family member [8].
GDF8 is also known as myostatin, which works as an inhibitor
of skeletal muscle growth and is a member of the TGF-beta family.
Myostatin has been suggested as a good candidate for therapeutic
intervention in diseases with loss of muscle mass, including
diabetes. Indeed, an increased expression of this gene has been
reported in skeletal muscle from chronic muscle wasting conditions
such as cachexia and aging in human and animal models [28–30].
Finding GDF8 (myostatin) to be upregulated in healthy first degree
relatives in this study suggests that this factor could play an
initiating role in the muscle wasting observed in many diabetic
patients and potentially in the development of insulin resistance in
the prediabetic stage.
The only gene with a know function found to have altered
expression levels in both the first degree relatives and the type 2
diabetics was LDHB. LDHB catalyzes the conversion of pyruvate
to lactate in the anaerobic glycolytic process and is therefore
crucial for normal energy homeostasis. Mitochondrial ATP
synthesis has been reported to be down in insulin resistant but
non-diabetic offspring of parents with type 2 diabetes as well as in
type 2 diabetic patients [31–32]. The results of this study suggest
that it is not only mitochondrial ATP production that is impaired
in these individuals but also ATP generation via the anaerobic
pathway. Since mitochondrial oxidative phosphorylation and
LDHB in a way compete for same pool of pyruvate it is also a
possibility that decreased levels of LDHB is a compensatory
mechanism in response to impaired mitochondrial function as
more pyruvate will be available for acetyl Coenzyme A
conversion.
Figure 4. Protein expression of IR and PGC1a. Western blot (WB) analyses were performed for the IR and PGC1a for all samples used in the
microarray study in order to verify mRNA results on protein level. Band intensities were determined and the average result for each group is shown in
this figure. The only significant difference between groups was found to be a downregulation of the IR in the diabetic group compared to controls
(unpaired t-test, p-value ,0.05). This result fits with what was observed in the microarray study.
doi:10.1371/journal.pone.0006575.g004
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type 2 diabetic skeletal muscle
Several interesting genes were found to be differentially
expressed in the ‘D’ group compared to controls using the dChip
program. One of the genes with the largest FCs is HK2
(FC=22.75, Table 2). This gene has previously been shown to
have an impaired expression in type 2 diabetic skeletal muscle
[33]. Furthermore, it has been shown that HK2 expression is
stimulated by insulin in healthy individuals but not in obese or
type 2 diabetes patients [34]. This can explain the decrease in
expression of HK2 in the type 2 diabetics since subjects were
submitted to a hyperinsulinemic clamp before samples were taken.
HDAC7A (histone deacetylase 7A) was also found to have a
reduced expression in muscle from type 2 diabetes patients
(FC=21.54, Table 2). It has previously been hypothesized that an
abnormal acetylation/deacetylation pattern and thereby an
altered regulation of gene expression could play a role in the
pathogenesis of type 2 diabetes [35].
In summary, this study for the first time shows a striking
difference in the gene expression of insulin signaling molecules
between people with type 2 diabetes and first degree relatives in
skeletal muscle. Insulin signaling was significantly upregulated in
first degree relatives, and significantly downregulated in type 2
diabetes patients. We suggest that increased expression of insulin
signaling molecules work in concert with increased levels of insulin
protecting people in the pre-diabetic state from insulin resistance
and metabolic dys-regulation. However, future studies are needed
to clarify the molecular basis and clinical importance of this
phenomenon, and it will be interesting to see if the same results
will be obtained in other tissues like pancreatic islets and adipose
tissue.
Furthermore, several potentially important genes regarding the
underlying causes of insulin resistance and type 2 diabetes (for
example KIF1B and GDF8) have been identified and shown to
have different gene expression levels in healthy first degree
relatives compared to controls. These new findings in first degree
relatives could potentially be used as a diagnostic tool in the
prediction of type 2 diabetes. Further investigations in the future
will be imperative in clarifying specific possible roles of these
results in type 2 diabetes pathogenesis.
Supporting Information
Figure S1 Validation of selected genes found to be differentially
expressed in skeletal muscle compared to healthy control samples
in a dChip analysis of the microarray results. Fold changes
obtained in the microarray study are compared to fold changes
obtained using qRT-PCR.The grey stabled line indicates the 1.2
cutoff. The qRT-PCR results are averages of two individual
experiments employing TagMan Low Density Arrays from
Applied Biosystems. A: People with type 2 diabetes. All genes
were found to be regulated in the same direction with both
methods. Two genes, RHEB and IRS2, did not live up to the FC
. 1.2 criteria using the qRT-PCR approach. B: First degree
relatives. All genes were found to be regulated in the same
direction with both methods. Two genes, COL1A1 and COL3A1,
did not live up to the FC . 1.2 criteria using the qRT-PCR
approach. C: Genes investigated by qRT-PCR that did not live up
to all criteria in the dChip analysis. The fold changes found for
type 2 diabetic muscle compared to controls are on the left side of
the figure, and fold changes found for skeletal muscle from first
degree relatives are depicted in the right part of the figure. For
standard deviations for qRT-PCR results please refer to Table S2.
Found at: doi:/10.1371/journal.pone.0006575.s001 (0.10 MB
DOC)
Table S1 Table showing all genes found to apply to all criteria
set in a dChip analysis comparing people with type 2 diabetes with
controls, and first degree relatives with controls. Fold changes (FC)
and gene names are listed.
Found at: doi:/10.1371/journal.pone.0006575.s002 (0.22 MB
DOC)
Table S2 Averages of biological replicate Ct values and their
standard deviation (SD). Ct values for 29 genes were determined
for all samples. The first degree relative and control groups
consisted of 15 people and each sample was run in two
independent experiments. The type 2 diabetes group consisted
of 5 people, and each sample was run in three independent
experiments. DCt values (normalization using endogenous control
value - in this case PPIA) and averages were calculated. Relative
fold changes were calculated as: FC=2-DDCt.
Found at: doi:/10.1371/journal.pone.0006575.s003 (0.09 MB
DOC)
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